POST Online Media Lite Edition



 

EMA approves two sites for production of Pfizer's COVID-19 vaccine

Christian Fernsby |
EMA’s human medicines committee (CHMP) has approved two additional manufacturing sites for the production of Comirnaty, the COVID-19 vaccine developed by BioNTech and Pfizer.

Article continues below




One site, located in Monza, Italy, is operated by Patheon Italia S.p.A. The other in Anagni, also in Italy, is operated by Catalent Anagni S.R.L. Both sites will manufacture finished product. These sites will produce up to 85 million additional doses to supply the EU in 2021.

These recommendations do not require a European Commission decision and the sites can become operational.


What to read next

Pfizer and BioNTech share positive early data on mRNA vaccine candidate BNT162b2 against coronavirus
Pfizer completes Hospira acquisition
Increased manufacturing capacity and supply for Spikevax